Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Among patients with triple-negative breast cancer, 5-year survival was 86.6% with neoadjuvant pembrolizumab with chemotherapy followed by adjuvant pembrolizumab and 81.7% with neoadjuvant chemotherapy alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology